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Abstract: Bisoprolol fumarate is a highly selective beta-1 receptor blocker. Bisoprolol has 
been extensively studied in three large mortality trials in stable chronic heart failure (CHF) 
patients. The CIBIS trial enrolled 641 patients and demonstrated the good tolerability of 
bisoprolol in a large CHF population, without evidence for any harmful effect. The CIBIS-II 
study was the ﬁ  rst large randomized, double-blind, placebo-controlled study demonstrating in 
2647 patients a dramatic reduction in mortality with a beta-blocking agent in CHF patients. 
CIBIS-III demonstrated in 1010 patients the equivalence of 2 different therapeutic strategies in 
de novo CHF patients. There was no difference in morbidity and mortality between sub-groups 
of patients receiving ﬁ  rst bisoprolol or enalapril. These three trials also demonstrated the good 
tolerability of bisoprolol fumarate. Other studies were either limited in number of patients or 
not randomized. However, these studies conﬁ  rmed the good tolerability of bisoprolol in CHF 
patients, even in elderly population. Bisoprolol fumarate is a selective beta-1 receptor blocker 
that signiﬁ  cantly reduced morbidity and mortality in stable CHF patients. Bisoprolol is well 
tolerated with few signiﬁ  cant side effects in different large trials. 
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Introduction
Chronic heart failure (CHF) represents a major health problem and is one of the leading 
causes of hospitalization, in particular in elderly patients. Medical treatment had 
signiﬁ  cantly improved during the last decade and several studies have demonstrated that 
angiotensin converting enzyme inhibitors (ACEI) and beta-blocker therapy are now the 
cornerstone of the treatment of patients with CHF (The SOLVD Investigators, 1991, 
1992; Pfeffer et al 1992; CIBIS-II investigators and Committees 1999; MERIT-HF 
study group 1999; Packer et al 2001; Flather et al 2005). In the 1970s, Waagstein and 
collaborators ﬁ  rst reported, in uncontrolled studies, that a treatment with a beta-blocker 
may dramatically improve symptoms and ventricular function in patients with mild to 
severe heart failure due to idiopathic dilated cardiomyopathy (Waagstein et al 1975; 
Swedberg et al 1979). Recently, different mortality trials have clearly demonstrated the 
beneﬁ  cial effects of beta-blocker therapy. However, other trials did not demonstrate 
a signiﬁ  cant mortality reduction (The Beta-Blocker Evaluation of Survival Trial 
Investigators 2001) or showed different effects between beta-blockers (Poole-Wilson 
et al 2003), leading international guidelines to recommend only 4 beta-blockers for 
CHF: bisoprolol, metoprolol succinate, carvedilol, and nebivolol (Hunt et al 2005; 
Swedberg et al 2005). Beta-blocker agents represent a large heterogeneous family with 
one important difference concerning receptor selectivity. In CHF, three recommended 
drugs are beta-1 adrenoreceptor blockers, namely bisoprolol, metoprolol succinate, and 
nebivolol, and one, carvedilol, is a beta-1–beta-2 adrenoreceptor blocker with additional 
alpha-1 vasodilatory activity. We will not focus our review on the comparison of these 
different beta-blockers. This review will summarize the results of different studies with Vascular Health and Risk Management 2007:3(4) 432
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bisoprolol in stable CHF patients, and particularly the 
different Cardiac Insufﬁ  ciency Bisoprolol Studies (CIBIS).
Pharmacokinetics of bisoprolol 
fumarate
Bisoprolol fumarate is a beta-1 receptor blocker, 
very freely soluble in water, with a molecular weight 
of 383.48 kDa (Leopold et al 1986; McGavin and 
Keating 2002). Bisoprolol is well absorbed after oral 
administration with a bioavailability of 90% and has a 
low plasma protein binding (30%). Food intake does not 
modify its biodisponibility. Bisoprolol is metabolized in 
the liver in inactive metabolites (50%) and eliminated 
(50%) via renal excretion without metabolisation. The 
plasma elimination half-life ranges from 10 to 12 hours. 
The pharmacokinetics of bisoprolol is minimally changed 
in patients with hepatic impairment or with a creatinine 
clearance between 10 and 30 mL/min. In patients with 
severe renal impairment (creatinine clearance <10 mL/
min), the exposure to bisoprolol is increased 2-fold. The 
plasma elimination half-life increases to 24.2 hours in 
the latter case (Kirch et al 1987).
There is limited information available on the pharmaco-
kinetics of bisoprolol in patients with stable heart failure. In 
NYHA class III patients, receiving a chronic treatment of 
10 mg/day, peak plasma concentrations were 78% higher, 
with a plasma elimination half-life reaching 17 hours.
Beta-receptor selectivity
Different experimental studies have demonstrated that 
bisoprolol fumarate is one of the most selective beta-1 
adrenoreceptor blockers, with a 19-fold higher affinity for 
the beta-1 receptor than for the beta-2 receptor (Wellstein 
et al 1986; Smith and Teilter 1999). Even at higher dose, 
there is no beta-2 blockade effect. Nebivolol is 3.5 times 
more beta-1 adrenoreceptor selective than bisoprolol in 
human myocardium and in vitro study (Bundkirchen 
et al 2003).
In a randomized, double-blind, placebo-controlled, 
cross-over study in 12 patients with stable angina pectoris 
and non-asthmatic chronic obstructive lung disease, a single 
dose of 100 mg of atenolol mg was compared with 20 mg 
of bisoprolol. Both drugs had a similar effect on heart rate 
but airway resistance increased with atenolol, whereas was 
unchanged with bisoprolol compared with placebo (Dorow 
et al 1986). Similar results were found in another randomized, 
double-blind, placebo-controlled, cross-over study in 12 
hypertensive asthmatic patients, comparing the airway 
resistance after the administration of 10 or 20 mg of bisoprolol, 
100 mg of atenolol, or placebo (Chatterjee 1986).
Efﬁ  cacy studies: CIBIS trials
Bisoprolol fumarate has the advantage to have been studied 
largely in 3 major mortality trials in stable CHF patients, 
demonstrating the important beneﬁ  ts of this beta-1 blocking 
agent and its good tolerability.
CIBIS
CIBIS was the first randomized, double-blind, 
placebo-controlled study with the primary objective of evalu-
ate the impact of bisoprolol on mortality in patients with heart 
failure (CIBIS Investigators and Committees 1994). The 
inclusion criteria were ambulatory CHF patients in NYHA 
class III-IV, with a left ventricular ejection fraction (LVEF) 
<40%, receiving diuretics and vasodilator therapy and not 
registered on a waiting list for heart transplantation. At this 
time, the tolerability of a chronic beta-blocker therapy was 
unknown in a large population. An important prerequisite 
before inclusion was the need of a clinical phase of stability, 
without any episode of heart failure decompensation and the 
absence of major modiﬁ  cation of heart failure therapy in the 
last 3 weeks before randomization. The initial dose of biso-
prolol was 1.25 mg once daily, which could be increased 48 
hours later to 2.5 mg/day and 1 month after to the maximal 
dose of 5 mg/day. It was not a forced titration procedure and 
each investigator was free to give to their patient, according 
to their clinical status, one of the four doses: 1.25, 2.5, 3.75, 
or 5 mg/day.
CIBIS enrolled 641 patients with CHF, in NYHA 
class III in the vast majority (609, 95%). Clinical char-
acteristics are summarized in Table 1. During a mean 
duration of follow-up of 1.9 ± 0.1 years, there were 120 
deaths, 67 (20.9%) in the placebo group and 53 (16.6%) 
in the bisoprolol group (Figure 1). This difference was 
not statistically signiﬁ  cant with a risk reduction of 0.80 
(0.56–1.15).
Despite this negative result, CIBIS was a very important 
study demonstrating the good tolerability of bisoprolol in 
a large CHF population, without evidence for any harmful 
effect of the beta-blocker therapy. Bisoprolol decreased the 
rate of hospitalization for worsening heart failure (107 (17%) 
compared with 154 (24%) in the placebo group, p < 0.001). 
Moreover, more patients in the bisoprolol group than in the 
placebo group improved their functional status. At the end 
of the trial, 21% of the patients receiving bisoprolol had an 
improvement of at least 1 class, compared with 15% in the Vascular Health and Risk Management 2007:3(4) 433
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Table 1 Clinical characteristics of the different CIBISa trials
  CIBIS  CIBIS II  CIBIS III
n 641  2647  1010
Age, years (mean)  59  61  72
Female 17%  19%  32%
NYHA class III/IV  95% / 5%  83% / 17%  50% / 0%
Ischemic heart failure  55%  50%  62%
Idiopathic dilated  36%  12%  10%
cardiomyopathy
ACEI 90%  96%  –
Diuretics 100%  99%  90%
Heart rate, bpm  83 ± 1.5  81 ± 15  79 ± 13
Systolic blood pressure,  126  130 ± 19  134 ± 17
mmHg
Diastolic blood pressure,  78  80 ± 11  80 ± 10
mmHg
LVEF (%)  25 ± 0.9  27 ± 6  28.8 ± 5
Mean dose bisoprolol, mg  3.8 ± 0.2   
afor CIBIS, quantitative results are presented as mean ± SEM.
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; CIBIS, Cardiac 
Insufﬁ  ciency Bisoprolol Studies; LVEF, left ventricular ejection fraction.
placebo group (p < 0.03). Deterioration of at least 1 NYHA 
class was similar in the two sub-groups (13% vs 11%).
CIBIS-II
The CIBIS-II study was the first large randomized, 
double-blind, placebo-controlled study demonstrating a 
dramatic reduction in mortality with a beta-blocking agent 
in CHF patients (CIBIS-II investigators and Committees 
1999). The equivalent study for the ACE-I was the 
CONSENSUS trial with enalapril (The CONSENSUS 
Trial Study Group 1987). CIBIS-II enrolled 2647 class 
III-IV stable CHF patients with a LVEF <35%, who were 
receiving diuretics and vasodilator therapy. In contrast 
to the CIBIS study, bisoprolol titration was forced to the 
maximal tolerated dose, with the highest possible dose of 
10 mg/day. The clinical characteristics of the CIBIS-II 
population are summarized in Table 1. Bisoprolol induced 
a signiﬁ  cant heart rate reduction (of 9.8 ± 14.7 beats/min), 
with a limited effect on blood pressure (systolic blood 
pressure reduction of 4.1 ± 16.4 mmHg with bisoprolol but 
of 2.3 ± 16.4 mmHg with placebo) (Lechat et al 2001).
The study was prematurely stopped because of the signiﬁ  -
cant mortality beneﬁ  t associated with bisoprolol (Figure 2). 
After a mean follow-up period of 1.3 years, there were 384 
deaths, with 228 (17.3%) deaths in the placebo arm and 156 
(11.8%) in the bisoprolol arm (hazard ratio (HR) of 0.66 
[0.54–0.81]). Bisoprolol signiﬁ  cantly reduced cardiovascular 
mortality (HR: 0.71 [0.56–0.9]), sudden cardiac death (HR: 
0.56 [0.39–0.80]), hospital admission (HR: 0.80 [0.71–0.91]), 
and hospital admission for worsening heart failure (HR: 0.64 
[0.53–0.79]) compared with placebo. The magnitude of the 
beneﬁ  t was similar in NYHA sub-classes, and independent of 
the etiology of heart failure. However, in patients with atrial 
ﬁ  brillation (n = 521, 20%), bisoprolol did not decrease total 
mortality when compared with placebo. This result must be 
Figure 1 Survival curves in CIBIS patients.Vascular Health and Risk Management 2007:3(4) 434
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taken with caution because of the limited number of patients 
with atrial ﬁ  brillation and the retrospective nature of the 
analysis (Lechat et al 2001). Although heart rate at baseline 
and heart rate reduction were independently associated with 
survival, there was no interaction with bisoprolol, suggesting 
that the beneﬁ  cial effect of bisoprolol was not inﬂ  uenced by 
these two parameters, and in particular by the extent of the 
heart rate reduction (Lechat et al 2001). In CIBIS, retrospective 
analysis suggested that patients with a LVEF 20% beneﬁ  t 
more from bisoprolol than other patients (Funck-Brentano et 
al 2000). However, this was not conﬁ  rmed in CIBIS-II, where 
the beneﬁ  cial effect of bisoprolol was independent of the level 
of left ventricular dysfunction.
CIBIS-III
The third important study with bisoprolol in CHF patients 
was designed to determine what drug to initiate in a de 
novo, stable, CHF patient, either ACEI or beta-blocker 
(Willenheimer et al 2005). Because the beneﬁ  cial effects of 
ACEI have been demonstrated ﬁ  rst (The CONSENSUS Trial 
Study Group 1987; The SOLVD Investigators 1991, 1992; 
Pfeffer et al 1992), all the subsequent studies have studied 
the impact on mortality of a new drug or device on top of 
ACEI (Pitt et al 1999; Cleland et al 2005). This question is of 
importance since the effects of beta-blockers in CHF patients 
are observed quickly after their introduction, in particular 
with a reduction of sudden cardiac death, which is the most 
prevalent cause of death in this population. Moreover, instead 
of ACEI that blocks one system, beta-blockers effectively 
inhibit 2 systems, the sympathetic system and the renin-
angiotensin system.
CIBIS-III was a multicenter, prospective, randomized, open 
label, blinded end-point evaluation study, with 2 parallel groups 
(Figure 3). Inclusion criteria were different from the previous 
CIBIS studies. Eligible patients were patients older than 65 
years, in NYHA class II or III, with a LVEF 35% and of 
course receiving neither ACEI nor beta-blocker. All patients 
were clinically stable for at least 7 days before the inclusion.
As in CIBIS-II, the titration was forced, depending on pa-
tient’s tolerance, for both drugs with a target dose of 10 mg/day 
for bisoprolol and of 20 mg/day for enalapril. After the titra-
tion, there was a 6-month monotherapy period, followed by 
a new titration in order to have the combination of enalapril 
and bisoprolol for a combined period. The primary end-point 
was the combination of all-cause mortality or all-cause hos-
pitalization. CIBIS-III was designed as a non-inferiority trial 
comparing the impact on the primary end-point of the initiation 
of bisoprolol ﬁ  rst compared with enalapril.
CIBIS-III enrolled 1010 patients who were followed during 
a mean period of 1.22 ± 0.42 years. Clinical characteristics of 
the study population are presented in Table 1. Because of the 
different inclusion criteria, some characteristics of CIBIS-III 
patients were different compared with those of patient enrolled 
in previous CIBIS studies. Patients in CIBIS-III were older, 
more often female, and less symptomatic (no NYHA class 
IV patients and half of the population was in NYHA class 
Figure 2 Survival curves in CIBIS-II patients.Vascular Health and Risk Management 2007:3(4) 435
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II). The results did not demonstrate any signiﬁ  cant difference 
between the two strategies (Figure 4). There were 178 patients 
with the primary end-point in the bisoprolol-ﬁ  rst group and 
186 in the enalapril-ﬁ  rst group (35.2 vs 36.8%). At the end 
of the monotherapy period, 109 bisoprolol-ﬁ  rst patients had a 
primary end-point compared with 108 enalapril-ﬁ  rst patients. 
There were fewer deaths in the bisoprolol-ﬁ  rst group than in 
the enalapril-ﬁ  rst group, but the difference was not statisti-
cally signiﬁ  cant (65 vs 73, HR: 0.88 [0.63–1.22], p = 0.44). 
There was a non-signiﬁ  cant increase in the number of patients 
having a hospitalization for worsening CHF in the bisoprolol-
ﬁ  rst group compared with the enalapril-ﬁ  rst group (63 vs 51 
patients, respectively, HR = 1.25 [0.87–1.81], p = 0.23). 
We can conclude, from the results of the CIBIS-III trial, 
that there was no difference in terms of efﬁ  cacy and safety 
between the two strategies of treatment initiation in stable 
CHF patients.
Non-mortality studies
There are few other studies with bisoprolol in CHF patients, 
but all these studies are either small or not randomized.
A small study analyzed the impact of bisoprolol on LVEF 
using magnetic resonance imaging (Dubach et al 2002). It 
was a randomized, double-blind study in 28 patients with a 
mean age of 57 years, 13 receiving bisoprolol and 15 placebo. 
Eight patients in each group had an ischemic cardiomyopathy 
and others had a dilated cardiomyopathy. All the patients 
were receiving ACEI and 24 were taking diuretics. The mean 
dose of bisoprolol was 7.19 mg/day. At baseline, at 6 months, 
and at 1 year after the introduction of bisoprolol, patients 
performed a cardiopulmonary exercise test and a magnetic 
resonance imaging of the heart. Bisoprolol produced a sig-
niﬁ  cant reduction in heart rate associated with a non-signiﬁ  -
cant increase in peak oxygen consumption. Left ventricular 
ejection fraction improved at 1 year only in the bisoprolol 
sub-group, from 25 ± 7% to 36.2 ± 9% (p < 0.05).
We performed an observational study in consecutive 
stable patients with CHF and LVEF <40% (de Groote et al 
2004). All the patients received maximal tolerated doses of 
renin inhibitors and were clinically stable at least 2 months 
before the introduction of bisoprolol. All the patients per-
formed a cardiopulmonary exercise test, and underwent a 
Figure 3 Study design of CIBIS-III. Double titration with monotherapy and combination phases for each arm, bisoprolol-ﬁ  rst and enalapril-ﬁ  rst.Vascular Health and Risk Management 2007:3(4) 436
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radionuclide angiography, before and 3 months after maximal 
tolerated doses of bisoprolol had been reached. Blood samples 
were drawn for hormonal determinations. We included 201 
patients, with a mean age of 54 ± 12 years; 34% had ischemic 
cardiomyopathy and the vast majority was in NYHA class 
I or II (75%). The mean dose of bisoprolol was 8.8 ± 2.4 
mg/day. Bisoprolol was associated with an improvement in 
NHYA functional class, and a signiﬁ  cant decrease in heart 
rate without any effect on blood pressure. There was a small 
signiﬁ  cant improvement in peak oxygen consumption (from 
16.1 ± 5 to 16.8 ± 5.5 mL/min/kg, p = 0.015) with a signiﬁ  cant 
decrease in peak expiratory exchange ratio for carbon dioxide 
production (from 38 ± 7.4 to 34 ± 6.7, p = 0.005). This 
suggests an improvement in the exercise ventilatory efﬁ  cacy 
with bisoprolol. LVEF improved from 31 ± 11 to 41 ± 13% 
(p < 0.0001). This favorable effect was associated with a 
reduction in ventricular volumes and with an improvement in 
the left ventricular ﬁ  lling function. Right ventricular ejection 
fraction also signiﬁ  cantly improved with bisoprolol. Finally, 
plasma levels of type A and type B natriuretic peptides and 
norepinephrine were signiﬁ  cantly reduced with bisoprolol. Of 
course, one of the biggest limitations of the study is the lack 
of a control group. However, at this time it was not ethical 
to give placebo to CHF patients.
In addition, another observational study in 87 CHF 
patients showed that beta-blockade improved LVEF in the 
majority of patients. However, significant improvement 
in LVEF did not enhance functional capacity consistently 
in CHF patients (Ennezat et al 2005).
Doses
In CIBIS and CIBIS-II, mean doses were significantly 
greater in the placebo arm compared with the bisoprolol 
arm. In CIBIS, respective doses were 4.5 ± 0.1 and 
3.8 ± 0.2 mg/day. Half of the patients received 5 mg of 
bisoprolol in CIBIS, and 43% reached 10 mg in CIBIS-II 
and 67% at least 5 mg/day. In CIBIS-III, during the mono-
therapy period, 65% of the patients reached the target 
dose in the bisoprolol-first group compared with 84% in 
the enalapril-first group. At the end of the study, in the 
bisoprolol-first group, 65% of the patients had the target 
dose of bisoprolol and 67% the target dose of enalapril. 
In the enalapril-first group, respective percentages were 
54% and 77%.
A retrospective analysis looking at the doses achieved 
after the forced titration in CIBIS-II revealed that patients in 
the lower tertile of doses were older, more often in NYHA 
class IV, and had a lower blood pressure. However, the 
Figure 4 Kaplan-Meier curves of the combined primary end-point (death or hospitalization) in CIBIS-III patients. Intention-to-treat analysis.Vascular Health and Risk Management 2007:3(4) 437
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beneﬁ  cial effect of bisoprolol was similar whatever the dose 
received (Simon et al 2003).
Tolerability of bisoprolol
Curiously, no precise information on non-serious adverse 
events is available from the three CIBIS studies. Bisoprolol 
is well tolerated. In CIBIS, percentages of patients with 
non-serious adverse events were similar in the 2 arms: 26% 
in the placebo group and 23% in the bisoprolol group. Two 
cases of sinus bradycardia and 2 cases of atrioventricular 
blockade were recorded in the bisoprolol group. Signiﬁ  cant 
hypotension was recorded in 3 patients in the placebo group 
and in 5 in the bisoprolol group. 
In CIBIS-II, the percentage of premature treatment with-
drawal was also similar in the 2 arms (15%), but there were 
more bradycardia with bisoprolol (14 vs 2, p < 0.004). The 
main cause of permanent treatment withdrawal was patient’s 
or investigator’s personal decision. Age (68 years) and 
heart rate at inclusion were both independent predictors of 
permanent treatment withdrawal. In patients with a heart rate 
<72 beats/min at inclusion, the risk of permanent bisopropol 
withdrawal was 1.97 (1.38–2.80). Of importance, the beneﬁ  cial 
mortality effect of bisoprolol was lost in patients having a per-
manent treatment withdrawal (Funck-Brentano et al 2001).
In CIBIS-III, during the monotherapy period, 35 patients 
(6.9%) had a permanent bisoprolol withdrawal compared with 
49 (9.7%) with enalapril. During the combination period, in 
the bisoprolol-ﬁ  rst group, 19 patients (4.2%) had a permanent 
withdrawal of bisoprolol and 47 patients (10.4%) a permanent 
withdrawal of enalapril. In the enalapril-ﬁ  rst group, corre-
sponding values were 24 (5.5%) and 16 (3.7%).
Different post-hoc analyses were performed from the 
CIBIS-II study population (Erdmann et al 2001). In CIBIS-II, 
a signiﬁ  cant and similar mortality reduction with bisoprolol 
was observed in the 539 CHF elderly patients (71 years) 
compared with younger patients (HR: 0.68 [0.48–0.97]). 
Although sudden death was not signiﬁ  cantly reduced in the 
elderly population, rates of pump failure death and CHF 
hospitalizations were reduced, with a similar permanent 
treatment withdrawal as compared with younger patients. 
These results were conﬁ  rmed by the meta-analysis of both 
CIBIS trials (Leizorovicz et al 2002).
Using the Cockroft Gault equation, 849 patients (32%) 
had renal impairment with a creatinine clearance <60 mL/min 
(Erdmann et al 2001). These patients had a similar beneﬁ  t 
with bisoprolol compared with patients who had a greater 
creatinine clearance. However, the rate of permanent treat-
ment withdrawal was signiﬁ  cantly higher in patients with 
renal impairment, reaching almost 25% in patients with a 
creatinine clairance <60 mL/min and 40% in the 63 patients 
with a creatinine clearance <30 mL/min.
Some other studies have looked at the tolerability of 
bisoprolol in CHF patients. A small study showed a similar 
tolerability of the initiation of carvedilol and bisoprolol in 
87 patients (Galatius et al 2004).
An observational study in elderly CHF patients analyzed 
the tolerability of bisoprolol. Patients included were older than 
70 years, in chronic NYHA class II or III, receiving diuretics 
and a renin system inhibitor and having a LVEF <40%. As 
for CIBIS, the inclusion in the study required a period of 6 
weeks of clinical stability before the introduction of bisoprolol 
(Baxter et al 2002). Baxter et al enrolled 51 patients with a 
mean age of 78 years, with 23 women. After the ﬁ  rst dose 
of 1.25 mg of bisoprolol, the majority of the patients had a 
hypotension (86%); in 28 of these patients, blood pressure fell 
below 100 mmHg and in 16 patients the blood pressure fall 
was greater than 20 mmHg but with a systolic blood pressure 
>100 mmHg. Of interest, despite a great frequency of hypoten-
sion, only 4 patients, all having a blood pressure <100 mmHg, 
experienced symptoms and complained dizziness.
During the titration period, 35 patients tolerated bisoprolol 
(69%) with a mean dose of 7.6 mg/day. The mean reason for 
withdrawal was hypotension in 7 patients (including the 4 
previous patients) and fatigue (3 other patients). Bradycardia 
was not a cause for bisoprolol withdrawal. Twenty-one 
patients tolerated 10 mg/day of bisoprolol and 9 received less 
than 5 mg/day. The main reasons for not reaching the target 
dose of 10 mg/day were hypotension in 7 cases, fatigue in 5 
cases, and bradycardia in 1 case.
In conclusion, this study showed that in elderly CHF 
patients, hypotension is the major symptom leading to 
treatment withdrawal or to keep low doses of bisoprolol. 
However, if bisoprolol was well tolerated, it was possible to 
reach the target dose of 10 mg/day without problem.
Another study looked at the tolerability of bisoprolol after 
its initiation by the primary care physicians (Schuchert 2005). 
This prospective study included 328 patients with stable 
CHF receiving diuretics and renin inhibitors. Mean age 
was 63 ± 10 years, and 145 patients were in NYHA class 
III and 1 in class IV. The maximal tolerated dose was 
7.2 ± 3.15 mg/day, 61% of the patients receiving at least 
7.5 mg of bisoprolol. NYHA class signiﬁ  cantly improved, 
from 2.4 ± 0.5 to 1.8 ± 0.6 (p < 0.0001) at the end of the 24 
week study period. At the end, 74% of the patients had an 
improvement and only 5% a worsening in functional class. 
Bisoprolol was withdrawn in 57 patients (17%), of whom Vascular Health and Risk Management 2007:3(4) 438
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40 related to adverse events. No patient had symptomatic 
bradycardia. This study demonstrated that bisoprolol could 
safely be introduced by primary care physician who did not 
have the same level of experience in CHF than physicians 
involved in the large mortality trials.
In summary, bisoprolol is well tolerated, even if in elderly 
patients treatment withdrawal seems to be more frequent than 
that observed in the large mortality trials. The main reason 
for not reaching the target dose of bisoprolol or for bisoprolol 
withdrawal is hypotension.
However, all the previous studies have excluded patients 
with resting heart rate <60 beats/min, patients with resting 
systolic blood pressure <100 mmHg and other main contra-
indications to beta-blocker such as asthmatic patients.
In the future, it will be important to have more informa-
tion about tolerance of bisoprolol in some subgroups of 
patients, in particular elderly patients (>75 years), patients 
with severe renal failure, patients with chronic obstructive 
pulmonary diseases, and patients in NYHA class IV.
Another important question is the management of CHF 
patients receiving chronic bisoprolol therapy and hospitalized 
for cardiac decompensation. Currently, the management of 
these patients depends on their clinical status and the expe-
rience of the practitioner. There are three possibilities: no 
modiﬁ  cation, reduction of the doses of beta-blocker (and it is 
often a half reduction of the dose), or transitory interruption 
of the beta-blocker. An ongoing French study, B-Convinced, 
will try to answer to this important question. This study was 
designed as a non-inferiority trial comparing two strategies 
after an acute CHF decompensation: to stop or to pursue the 
beta-blocker.
Finally, another unresolved question is to know how long 
the beneﬁ  cial effects of beta-blocker therapy in CHF patients 
will be maintained.
Conclusions
Bisoprolol fumarate is a potent, highly selective beta-1 
adrenergic blocker. Large mortality trials have clearly dem-
onstrated the beneﬁ  cial effects of bisoprolol on mortality and 
on morbidity compared with placebo. These favorable effects 
are associated with a reverse remodelling of the left ventricle 
and a signiﬁ  cant improvement in LVEF. Finally, bisoprolol 
is well tolerated, with a limited number of side effects leading 
to its permanent withdrawal.
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